-
Exelixis Inc (NASDAQ:EXEL) granted Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide rights its preclinical phosphoinositide 3-kinase (PI3K) delta program, including lead inhibitor XL499 and related compounds. Exelixis …
Published on 12/21/2011
-
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire cancer company Intellikine Inc. (La Jolla, Calif.) for $190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128, an …
Published on 12/20/2011
-
Amgen Inc. (NASDAQ:AMGN) and Watson Pharmaceuticals Inc. (NYSE:WPI) partnered to co-develop and commercialize biosimilars of cancer antibodies worldwide. Amgen will be responsible for developing, manufacturing and …
Published on 12/19/2011
-
FDA expects to receive only one or two biosimilar marketing applications through the beginning of 2014, Theresa Mullin, director of FDA's Office of Planning and Informatics, told BioCentury Friday. She said FDA expects …
Published on 12/16/2011
-
InterMune Inc. (NASDAQ:ITMN) was off $5.55 (30%) to $12.74 on Thursday after Germany's health technology assessment agency said Esbriet pirfenidone provides "no additional benefit" compared with best supportive care in …
Published on 12/15/2011
-
ViroPharma Inc. (NASDAQ:VPHM) gained $4.21 (18%) to $27.80 on Wednesday after FDA approved a new label for antibiotic Vancocin vancomycin that the company said could provide additional protection against generic …
Published on 12/14/2011
-
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.16 (25%) to $0.78 on Tuesday after FDA's Psychopharmacologic Drugs Advisory Committee voted 9-8, with one abstention, in favor of recommending approval of inhaled …
Published on 12/13/2011
-
Reata Pharmaceuticals Inc. (Irving, Texas) partnered with Abbott Laboratories (NYSE:ABT) to co-develop and co-commercialize Reata's portfolio of second-generation antioxidant inflammation modulators (AIMs) worldwide. …
Published on 12/12/2011
-
Pharmacyclics Inc. (NASDAQ:PCYC) fell $2.23 (15%) to $12.39 on Friday after announcing a partnership late Thursday with Janssen Biotech Inc. to co-develop and co-commercialize Pharmacyclics' hematological cancer …
Published on 12/9/2011
-
Pharmacyclics Inc. (NASDAQ:PCYC) partnered with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech Inc. to co-develop and co-commercialize Pharmacyclics' hematological cancer compound PCI-32765. Pharmacyclics will …
Published on 12/8/2011
-
FDA's Oncologic Drugs Advisory Committee voted 15-1 with one abstention that peginesatide from Affymax Inc. (NASDAQ:AFFY) has a favorable benefit-risk profile to treat anemia in patients with chronic kidney disease who …
Published on 12/7/2011
-
Biogen Idec Inc. (NASDAQ:BIIB) partnered with Samsung Group (Seoul, South Korea) to form a 15/85 JV to develop and commercialize biosimilars. Samsung will contribute $255 million, while Biogen Idec will contribute $45 …
Published on 12/6/2011
-
Affymax Inc. (NASDAQ:AFFX) gained $1.01 (19%) to $6.26 on Monday after FDA agreed that peginesatide is non-inferior to marketed erythropoiesis-stimulating agents (ESAs) in maintaining hemoglobin levels in chronic kidney…
Published on 12/5/2011
-
Germany's health technology assessment agency said HCV drug Victrelis boceprevir plus peginterferon and ribavirin -- standard of care -- provides an "important additional benefit" compared to standard of care alone in …
Published on 12/2/2011
-
Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) was up $1.51 (22%) to $8.48 on Thursday after Purdue Pharma L.P. (Stamford, Conn.) exercised an option to commercialize newly approved insomnia therapy Intermezzo zolpidem in…
Published on 12/1/2011
-
The U.K.'s NICE issued a second draft guidance recommending against Gilenya fingolimod to treat relapsing-remitting multiple sclerosis (RRMS), despite a discount proposed by Novartis AG (NYSE:NVS; SIX:NOVN) after a …
Published on 11/30/2011
-
PTC Therapeutics Inc. (South Plainfield, N.J.) granted Roche (SIX:ROG; OTCQX:RHHYB) exclusive, worldwide rights to its spinal muscular atrophy (SMA) program, which includes three small molecules in preclinical testing …
Published on 11/29/2011
-
AstraZeneca plc (LSE:AZN; NYSE:AZN) committed an additional $100 million to MedImmune Ventures, bringing the total capital under management by the VC arm to $400 million. MedImmune Ventures invests in biopharmaceutical …
Published on 11/28/2011
-
The U.K.'s NICE issued draft guidance recommending against Lucentis ranibizumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat macular edema secondary to central retinal vein occlusion (CRVO) or branch retinal vein …
Published on 11/23/2011
-
Prospect Venture Partners said Managing Director Alex Barkas died unexpectedly on Monday. Barkas, 64, joined Prospect in 1997 from Kleiner Perkins Caufield & Byers, where he was a partner from 1991-97. He was the …
Published on 11/22/2011
-
Gilead Sciences Inc. (NASDAQ:GILD) will acquire HCV company Pharmasset Inc. (NASDAQ:VRUS) for $137 per share in cash. The price is an 89% premium to Pharmasset's close of $72.67 on Friday, before the deal was announced,…
Published on 11/21/2011
-
FDA Commissioner Margaret Hamburg revoked accelerated approval of Avastin bevacizumab in combination with paclitaxel for HER2-negative metastatic breast cancer (mBC). Hamburg encouraged Genentech Inc. to continue to …
Published on 11/18/2011
-
Diagnostic systems provider Biocartis S.A. (Lausanne, Switzerland) raised EUR 71 million ($97.5 million) in a series C round from Debiopharm Group (Lausanne, Switzerland); Royal Philips Electronics N.V. (NYSE:PHG; …
Published on 11/17/2011
-
Clovis Oncology Inc. (NASDAQ:CLVS) raised $130 million through the sale of 10 million shares at $13 per share in an IPO underwritten by JPMorgan; Credit Suisse; and Leerink. The price values Clovis at about $279.1 …
Published on 11/16/2011
-
Geron Corp. (NASDAQ:GERN) fell $0.45 (20%) to $1.75 on Tuesday after discontinuing its stem cell programs. The company, which is seeking partners for the assets, made the decision after a review of the "costs, value …
Published on 11/15/2011